STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures, IP Group and Taiho Ventures LLC who share the founders’ ambitions to build a world-leading company in the field. To date, STORM Therapeutics has raised £16million of funding.
STORM Therapeutics raised its series A in 2016 and has built an experienced team who occupy modern, well-equipped laboratories on the Babraham Research Campus, Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (eg Evotec) enabling STORM to operate a cost efficient and flexible model.